Trials / Completed
CompletedNCT02279953
Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To assess the efficacy of vortioxetine (10 to 20 mg/day) as adjunctive treatment to stable selective serotonin reuptake inhibitor (SSRI) dose versus stable SSRI monotherapy on cognitive performance (focusing on the aspect concerning speed of processing, executive functioning and attention) in patients who are in partial or full remission from their Major Depressive Episode (MDE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vortioxetine 10-20 mg | |
| DRUG | Placebo | |
| DRUG | SSRI | escitalopram, citalopram or sertraline |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2014-10-31
- Last updated
- 2017-05-24
Locations
17 sites across 5 countries: Estonia, Finland, Germany, Serbia, Slovakia
Source: ClinicalTrials.gov record NCT02279953. Inclusion in this directory is not an endorsement.